ML Strategies has posted its weekly Health Care Update. This publication provides timely information on implementation of the Affordable Care Act, Congressional initiatives affecting the health care industry, and federal and state health regulatory developments.
Last week was a big week for the 340B drug program, when a federal judge ruled that HRSA did not have authority to create exceptions for 340B use for orphan drugs. What this means for the upcoming “mega-rule” that will determine how the 340B program is administered will probably be one of the top issues for the remainder of 2014. In other news, the Food and Drug Administration (FDA) approved the drug Dalvance, an antibacterial to treat adult skin infections which comes at a time when fewer antibiotics are being approved. Finally, continuing on last week’s theme, CMS announced more moves to release public data around Medicare reimbursement, utilization, and price.
Click here to read this week's Health Care Update.